Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IQP 0528

Drug Profile

IQP 0528

Alternative Names: DuoGel; IQP-0528

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samjin Pharmaceutical Company
  • Developer ImQuest Life Sciences; John Hopkins University; National Institute of Allergy and Infectious Diseases
  • Class Antivirals; Pyrimidinones; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 02 Jun 2019 Johns Hopkins University ImQuest Pharmaceuticals National Institute of Allergy and Infectious Diseases completes a phase I trial for HIV infections (Prevention) in USA (Rectal) (NCT03082690)
  • 01 Nov 2017 Phase-I clinical trials in HIV infections (Prevention) in USA (Rectal) (NCT03082690)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top